Fanyue Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fanyue Shao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Guohua Mao
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
2 shared publications - Jihui Hao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, China
2 shared publications - Jingbo Xu
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
2 shared publications - Jingrui Yan
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
2 shared publications - Shangheng Shi
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
2 shared publications - Tianxing Zhou
Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
2 shared publications
Latest Publications
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps
Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination treatment strategies. In this study, we used a dormancy-tracking system to show that chemotherapy awakens dormant disseminated tumor cells (DTC) in the liver by inducing hepatocyte senescence and subsequent neutrophil extracellular trap (NET) formation. In human and mouse cohorts, adjuvant and neoadjuvant chemotherapy triggered hepatocyte senescence, leading to TGFβ secretion and SMAD-dependent NETosis. NET-derived DNA engaged the transmembrane receptor CCDC25 on dormant DTCs, activating PI3K–AKT signaling and reprogramming DTCs toward a lipid-laden, proliferative phenotype. Genetic or pharmacologic disruption of NET formation, TGFβ signaling, or CCDC25 function effectively suppressed DTC reactivation and hepatic metastasis without compromising chemotherapy efficacy. Clinically, elevated serum NET-DNA levels correlated with hepatocyte senescence, DTC proliferation, and poor survival in PDAC and other solid tumors. Taken together, these findings unveil a senescence–NET–CCDC25 axis that links chemotherapy-induced tissue damage to metastatic relapse, providing a mechanistic basis for adjuvant and neoadjuvant strategies targeting NETosis and CCDC25 to prevent recurrence in PDAC. Significance: Chemotherapy induces hepatocyte senescence and neutrophil extracellular trap formation that activates CCDC25 signaling to awaken dormant disseminated pancreatic cancer cells in the liver, providing mechanistic insights and therapeutic opportunities for preventing relapse.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps
Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination treatment strategies. In this study, we used a dormancy-tracking system to show that chemotherapy awakens dormant disseminated tumor cells (DTC) in the liver by inducing hepatocyte senescence and subsequent neutrophil extracellular trap (NET) formation. In human and mouse cohorts, adjuvant and neoadjuvant chemotherapy triggered hepatocyte senescence, leading to TGFβ secretion and SMAD-dependent NETosis. NET-derived DNA engaged the transmembrane receptor CCDC25 on dormant DTCs, activating PI3K–AKT signaling and reprogramming DTCs toward a lipid-laden, proliferative phenotype. Genetic or pharmacologic disruption of NET formation, TGFβ signaling, or CCDC25 function effectively suppressed DTC reactivation and hepatic metastasis without compromising chemotherapy efficacy. Clinically, elevated serum NET-DNA levels correlated with hepatocyte senescence, DTC proliferation, and poor survival in PDAC and other solid tumors. Taken together, these findings unveil a senescence–NET–CCDC25 axis that links chemotherapy-induced tissue damage to metastatic relapse, providing a mechanistic basis for adjuvant and neoadjuvant strategies targeting NETosis and CCDC25 to prevent recurrence in PDAC. Significance: Chemotherapy induces hepatocyte senescence and neutrophil extracellular trap formation that activates CCDC25 signaling to awaken dormant disseminated pancreatic cancer cells in the liver, providing mechanistic insights and therapeutic opportunities for preventing relapse.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (2) , 207-212
Senescence as the Next Frontier in Cancer Research: Navigating the Rising Tide of Geriatric Oncology
Summary: The global demographic shift toward an aging population has positioned cancer as a preeminent challenge in public health, with the incidence of most malignancies increasing precipitously with advancing age. By targeting the bidirectional nexus of cancer and aging, we can pioneer precision interventions to improve outcomes for the growing geriatric oncology population.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (2) , 207-212
Senescence as the Next Frontier in Cancer Research: Navigating the Rising Tide of Geriatric Oncology
Summary: The global demographic shift toward an aging population has positioned cancer as a preeminent challenge in public health, with the incidence of most malignancies increasing precipitously with advancing age. By targeting the bidirectional nexus of cancer and aging, we can pioneer precision interventions to improve outcomes for the growing geriatric oncology population.